199 related articles for article (PubMed ID: 34082789)
1. Treatment adherence in tyrosinemia type 1 patients.
González-Lamuño D; Sánchez-Pintos P; Andrade F; Couce ML; Aldámiz-Echevarría L
Orphanet J Rare Dis; 2021 Jun; 16(1):256. PubMed ID: 34082789
[TBL] [Abstract][Full Text] [Related]
2. Evolution of tyrosinemia type 1 disease in patients treated with nitisinone in Spain.
Couce ML; Sánchez-Pintos P; Aldámiz-Echevarría L; Vitoria I; Navas V; Martín-Hernández E; García-Volpe C; Pintos G; Peña-Quintana L; Hernández T; Gil D; Sánchez-Valverde F; Bueno M; Roca I; López-Ruzafa E; Díaz-Fernández C
Medicine (Baltimore); 2019 Sep; 98(39):e17303. PubMed ID: 31574857
[TBL] [Abstract][Full Text] [Related]
3. Effect of nitisinone (NTBC) treatment on the clinical course of hepatorenal tyrosinemia in Québec.
Larochelle J; Alvarez F; Bussières JF; Chevalier I; Dallaire L; Dubois J; Faucher F; Fenyves D; Goodyer P; Grenier A; Holme E; Laframboise R; Lambert M; Lindstedt S; Maranda B; Melançon S; Merouani A; Mitchell J; Parizeault G; Pelletier L; Phan V; Rinaldo P; Scott CR; Scriver C; Mitchell GA
Mol Genet Metab; 2012 Sep; 107(1-2):49-54. PubMed ID: 22885033
[TBL] [Abstract][Full Text] [Related]
4. Oxidative Stress, Glutathione Metabolism, and Liver Regeneration Pathways Are Activated in Hereditary Tyrosinemia Type 1 Mice upon Short-Term Nitisinone Discontinuation.
Colemonts-Vroninks H; Neuckermans J; Marcelis L; Claes P; Branson S; Casimir G; Goyens P; Martens GA; Vanhaecke T; De Kock J
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33375092
[TBL] [Abstract][Full Text] [Related]
5. Early effect of NTBC on renal tubular dysfunction in hereditary tyrosinemia type 1.
Maiorana A; Malamisura M; Emma F; Boenzi S; Di Ciommo VM; Dionisi-Vici C
Mol Genet Metab; 2014 Nov; 113(3):188-93. PubMed ID: 25172236
[TBL] [Abstract][Full Text] [Related]
6. Daily variation of NTBC and its relation to succinylacetone in tyrosinemia type 1 patients comparing a single dose to two doses a day.
Kienstra NS; van Reemst HE; van Ginkel WG; Daly A; van Dam E; MacDonald A; Burgerhof JGM; de Blaauw P; McKiernan PJ; Heiner-Fokkema MR; van Spronsen FJ
J Inherit Metab Dis; 2018 Mar; 41(2):181-186. PubMed ID: 29170874
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Various Doses of Phenylalanine Supplementation on Blood Phenylalanine and Tyrosine Concentrations in Tyrosinemia Type 1 Patients.
van Ginkel WG; van Reemst HE; Kienstra NS; Daly A; Rodenburg IL; MacDonald A; Burgerhof JGM; de Blaauw P; van de Krogt J; Santra S; Heiner-Fokkema MR; van Spronsen FJ
Nutrients; 2019 Nov; 11(11):. PubMed ID: 31752110
[TBL] [Abstract][Full Text] [Related]
8. LC-MS/MS method for simultaneous determination on a dried blood spot of multiple analytes relevant for treatment monitoring in patients with tyrosinemia type I.
la Marca G; Malvagia S; Materazzi S; Della Bona ML; Boenzi S; Martinelli D; Dionisi-Vici C
Anal Chem; 2012 Jan; 84(2):1184-8. PubMed ID: 22148291
[TBL] [Abstract][Full Text] [Related]
9. Laboratory monitoring of patients with hereditary tyrosinemia type I.
Schultz MJ; Netzel BC; Singh RH; Pino GB; Gavrilov DK; Oglesbee D; Raymond KM; Rinaldo P; Tortorelli S; Smith WE; Matern D
Mol Genet Metab; 2020 Aug; 130(4):247-254. PubMed ID: 32546364
[TBL] [Abstract][Full Text] [Related]
10. Emotional and behavioral problems, quality of life and metabolic control in NTBC-treated Tyrosinemia type 1 patients.
van Vliet K; van Ginkel WG; Jahja R; Daly A; MacDonald A; De Laet C; Vara R; Rahman Y; Cassiman D; Eyskens F; Timmer C; Mumford N; Bierau J; van Hasselt PM; Gissen P; Goyens PJ; McKiernan PJ; Wilcox G; Morris AAM; Jameson EA; Huijbregts SCJ; van Spronsen FJ
Orphanet J Rare Dis; 2019 Dec; 14(1):285. PubMed ID: 31801588
[TBL] [Abstract][Full Text] [Related]
11. Hereditary tyrosinemia type 1 in Turkey: twenty year single-center experience.
Zeybek AC; Kiykim E; Soyucen E; Cansever S; Altay S; Zubarioglu T; Erkan T; Aydin A
Pediatr Int; 2015 Apr; 57(2):281-9. PubMed ID: 25223216
[TBL] [Abstract][Full Text] [Related]
12. Tyrosinemia type 1 in Spain: mutational analysis, treatment and long-term outcome.
Couce ML; Dalmau J; del Toro M; Pintos-Morell G; Aldámiz-Echevarría L;
Pediatr Int; 2011 Dec; 53(6):985-9. PubMed ID: 21752152
[TBL] [Abstract][Full Text] [Related]
13. Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I.
Al-Dhalimy M; Overturf K; Finegold M; Grompe M
Mol Genet Metab; 2002 Jan; 75(1):38-45. PubMed ID: 11825062
[TBL] [Abstract][Full Text] [Related]
14. The Québec NTBC Study.
; Alvarez F; Atkinson S; Bouchard M; Brunel-Guitton C; Buhas D; Bussières JF; Dubois J; Fenyves D; Goodyer P; Gosselin M; Halac U; Labbé P; Laframboise R; Maranda B; Melançon S; Merouani A; Mitchell GA; Mitchell J; Parizeault G; Pelletier L; Phan V; Turcotte JF
Adv Exp Med Biol; 2017; 959():187-195. PubMed ID: 28755196
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1.
van Ginkel WG; Rodenburg IL; Harding CO; Hollak CEM; Heiner-Fokkema MR; van Spronsen FJ
Paediatr Drugs; 2019 Dec; 21(6):413-426. PubMed ID: 31667718
[TBL] [Abstract][Full Text] [Related]
16. A Lithuanian Case of Tyrosinemia Type 1 with a Literature Review: A Rare Cause of Acute Liver Failure in Childhood.
Rokaitė R; Čibirkaitė A; Zeleckytė V; Lazdinytė G; Dženkaitis M
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256395
[TBL] [Abstract][Full Text] [Related]
17. Natural Protein Tolerance and Metabolic Control in Patients with Hereditary Tyrosinaemia Type 1.
Yilmaz O; Daly A; Pinto A; Ashmore C; Evans S; Gupte G; Santra S; Preece MA; Mckiernan P; Kitchen S; Ayhan NY; MacDonald A
Nutrients; 2020 Apr; 12(4):. PubMed ID: 32325917
[TBL] [Abstract][Full Text] [Related]
18. Impaired cognitive functioning in patients with tyrosinemia type I receiving nitisinone.
Bendadi F; de Koning TJ; Visser G; Prinsen HC; de Sain MG; Verhoeven-Duif N; Sinnema G; van Spronsen FJ; van Hasselt PM
J Pediatr; 2014 Feb; 164(2):398-401. PubMed ID: 24238861
[TBL] [Abstract][Full Text] [Related]
19. Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.
Mayorandan S; Meyer U; Gokcay G; Segarra NG; de Baulny HO; van Spronsen F; Zeman J; de Laet C; Spiekerkoetter U; Thimm E; Maiorana A; Dionisi-Vici C; Moeslinger D; Brunner-Krainz M; Lotz-Havla AS; Cocho de Juan JA; Couce Pico ML; Santer R; Scholl-Bürgi S; Mandel H; Bliksrud YT; Freisinger P; Aldamiz-Echevarria LJ; Hochuli M; Gautschi M; Endig J; Jordan J; McKiernan P; Ernst S; Morlot S; Vogel A; Sander J; Das AM
Orphanet J Rare Dis; 2014 Aug; 9():107. PubMed ID: 25081276
[TBL] [Abstract][Full Text] [Related]
20. Dietary Considerations in Tyrosinemia Type I.
van Spronsen FJ; van Rijn M; Meyer U; Das AM
Adv Exp Med Biol; 2017; 959():197-204. PubMed ID: 28755197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
